GlassScriptPhysician profile
Bernard S Zoranski
NPI 1184625840
$20,022.32
in general payments reported to CMS, 2019-2025
57 companies · $2,794 in 2025
The $2,794 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,902 · 2020: $2,304 · 2021: $2,953 · 2022: $3,193 · 2023: $2,853 · 2024: $3,024 · 2025: $2,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,671.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,994.05 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Astrazeneca Pharmaceuticals LP | $2,837.08 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,839.30 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,404.25 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $1,313.02 | 2019-2025 | |
| Allergan, INC. | $1,055.01 | 2019-2020 | |
| Glaxosmithkline, LLC. | $1,049.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $825.68 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $684.34 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.41 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $456.24 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $421.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $408.50 | 2019-2022 | |
| Axsome Therapeutics, INC. | $296.02 | 2024-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $278.30 | 2019-2023 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Zoranski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.